Cover Image
Market Research Report
Product code 
199796

Scar - Pipeline Review, H2 2019

Published: | Global Markets Direct | 75 Pages | Delivery time: 1-2 business days

Price

Back to Top
Scar - Pipeline Review, H2 2019
Published: November 25, 2019
Global Markets Direct
Content info: 75 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Scar - Pipeline Review, H2 2019, provides an overview of the Scar (Dermatology) pipeline landscape.

A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red to purple fibrous tissue that over time usually becomes flatter and lighter in color.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Scar - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Scar (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Scar (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Scar and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 5, 8 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Scar (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Scar (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Scar (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Scar (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Scar (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Scar (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Scar (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Scar (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Product Code: GMDHC11559IDB

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Scar - Overview
  • Scar - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Scar - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Scar - Companies Involved in Therapeutics Development
    • Axolo Pharma Inc
    • BirchBioMed Inc
    • Cotinga Pharmaceuticals Inc
    • CSA Biotechnologies LLC
    • Ember Therapeutics Inc (Inactive)
    • FBM Therapeutics LLC
    • Kringle Pharma Inc
    • Moerae Matrix Inc
    • Pharmaxis Ltd
    • Phio Pharmaceuticals Corp
    • Promore Pharma AB
    • Resolys Bio Inc
    • ScarTec Therapeutics BV
    • Synedgen Inc
    • Temple Therapeutics BV
  • Scar - Drug Profiles
    • albuterol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BTL-slo - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • decorin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Evitar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FBM-5712 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FS-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ICX-RHY - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KP-100IT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MG-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MMI-0100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Fibrotic Scar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide for Scar and Pancreatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polysaccharide for Wounds and Scars - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PXL-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXI-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Lysyl Oxidase for Scar and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Scar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit SOX-9 for Scar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Scar - Dormant Projects
  • Scar - Discontinued Products
  • Scar - Product Development Milestones
    • Featured News & Press Releases
      • Feb 28, 2019: First patient enrolled in BirchBioMed's study investigating FS2 for the treatment of scars
      • Feb 01, 2019: Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study
      • Oct 23, 2018: Promore Pharma has had a successful meeting with the FDA regarding PXL01
      • Sep 03, 2018: Promore Pharma plans to expand indications of therapeutic peptide PXL01 in the field of dermal scarring
      • May 08, 2018: Rxi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO
      • Feb 16, 2018: BirchBioMed is cleared to begin first-of-its-kind phase II clinical trial for ground-breaking anti-scarring drug
      • Feb 15, 2018: Promore Pharma Regains Rights for PXL01 Manufacturing
      • Feb 01, 2018: Promore Pharma is granted a patent for PXL01 in the US
      • Jan 02, 2018: Promore Pharma Adjusts Plans for PXL01 in North America
      • Dec 18, 2017: Rxi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring
      • May 17, 2017: Promore Pharma files phase III clinical trial application in India
      • Mar 28, 2017: Rxi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109
      • Aug 25, 2016: BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug
      • Apr 28, 2016: Rxi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
      • Apr 25, 2016: Rxi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Scar, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 4: Products under Development by Companies, H2 2019
  • Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 6: Products under Development by Universities/Institutes, H2 2019
  • Table 7: Number of Products by Stage and Target, H2 2019
  • Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 9: Number of Products by Stage and Route of Administration, H2 2019
  • Table 10: Number of Products by Stage and Molecule Type, H2 2019
  • Table 11: Scar - Pipeline by Axolo Pharma Inc, H2 2019
  • Table 12: Scar - Pipeline by BirchBioMed Inc, H2 2019
  • Table 13: Scar - Pipeline by Cotinga Pharmaceuticals Inc, H2 2019
  • Table 14: Scar - Pipeline by CSA Biotechnologies LLC, H2 2019
  • Table 15: Scar - Pipeline by Ember Therapeutics Inc (Inactive), H2 2019
  • Table 16: Scar - Pipeline by FBM Therapeutics LLC, H2 2019
  • Table 17: Scar - Pipeline by Kringle Pharma Inc, H2 2019
  • Table 18: Scar - Pipeline by Moerae Matrix Inc, H2 2019
  • Table 19: Scar - Pipeline by Pharmaxis Ltd, H2 2019
  • Table 20: Scar - Pipeline by Phio Pharmaceuticals Corp, H2 2019
  • Table 21: Scar - Pipeline by Promore Pharma AB, H2 2019
  • Table 22: Scar - Pipeline by Resolys Bio Inc, H2 2019
  • Table 23: Scar - Pipeline by ScarTec Therapeutics BV, H2 2019
  • Table 24: Scar - Pipeline by Synedgen Inc, H2 2019
  • Table 25: Scar - Pipeline by Temple Therapeutics BV, H2 2019
  • Table 26: Scar - Dormant Projects, H2 2019
  • Table 27: Scar - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Table 28: Scar - Discontinued Products, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Scar, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Targets, H2 2019
  • Figure 5: Number of Products by Stage and Targets, H2 2019
  • Figure 6: Number of Products by Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
  • Figure 10: Number of Products by Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019